16 March 2009: Today is the  first day  in the  first possible  exercise period  for warrants in the  form of  Class A Warrants  and Class  B Warrants  in NorDiag. Class A Warrants and Class  B Warrants may in this  instance be exercised in the period 15-31 March 2009.

According to the resolution by  the extraordinary general meeting  19 December 2008 and the prospectus regarding the rights issue, dated 15 January 2009, the  Class A Warrants  and Class B  Warrants that  were issued in connection with the rights  issue may only be exercised  in the periods 15-31  March, 15-30  June, 15-30  September and/or  15-31 December. Class A  Warrants are  exercisable up to  and including  30 September 2009,  while Class  B Warrants  are exercisable  up to  and including 30 June 2010. In connection with the rights issue in NorDiag, which was  registered on 19 February 2009, 38,607,058 Class A Warrants and 38,607,058 Class B  Warrants  were  issued   and  allotted. In  addition, 4,080,000 C-warrants were issued and allotted  to employees in the company  and its subsidiaries. C-warrants are exercisable  up to and including  31 December 2011, provided, however, that  exercise may only take  place in the periods 15-30 June and/or 15-31 December. Hence, only Class  A Warrants and Class B Warrants may be exercised  in the period  15-31 March.

Each Class A Warrant and each Class B Warrant gives the right to require issued one new share in NorDiag, each with a nominal value of NOK 0.10, with a subscription price of NOK 0.50.

According to the resolution by the general meeting, Class A Warrants and Class B Warrants shall be exercised by way of written notification to the company's Board of Directors, clearly instructing the company that the subscription right shall be exercised, and including the number of shares to be subscribed.

The company requests that such instructions are mailed or given to Orion Securities AS, attn. Carl I. Hole, Rådhusgaten 25, P.O.Box 236 Sentrum, 0103 Oslo, Norway (phone: +47 21 00 29 58 / fax: +47 21 00 29 31).

Contact:
CEO Mårten Wigstøl                      Phone + 47 911 65775
CFO Tone Kvåle                            Phone + 47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the notice in Norwegian here